Coya Therapeutics, Inc.
Clinical-stage biotech developing therapies to enhance regulatory T cell function.
COYA | US
Overview
Corporate Details
- ISIN(s):
- US22407B1089
- LEI:
- Country:
- United States of America
- Address:
- 12645 MEMORIAL DR., SUITE F1 #305, 77024 HOUSTON
- Sector:
- Manufacturing
Description
Coya Therapeutics, Inc. is a clinical-stage biotechnology company that develops proprietary biologics and multi-modality therapies designed to enhance the function of regulatory T cells (Tregs). The company's approach focuses on modulating dysfunctional Tregs to suppress inflammation associated with neurodegenerative, autoimmune, and metabolic diseases. Its lead product candidate, COYA 302, is an investigational biologic combination therapy being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS). The pipeline also includes other candidates such as COYA 303, a combination of low-dose Interleukin-2 (IL-2) and a GLP-1 receptor agonist, intended for inflammation-driven diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Coya Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Coya Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Coya Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
